

# PATENT

## UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application  
Commissioner of Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is the patent application  
under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: DEAV2002/0056 US NP

INVENTORS: STROBEL, et al.

TITLE: ACYLAmino-SUBSTITUTED HETEROAROMATIC  
COMPOUNDS AND THEIR USE AS  
PHARMACEUTICALS

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
Express Mail in an envelope addressed to Mail Stop  
Patent Application, Commissioner of Patents, P.O.  
Box 1450, Arlington, VA 22313-1450, on

August 5, 2003

Date of Deposit

Signature

EV 242704261 US

Express Mail No.

03943 U.S. PTO  
10/634979  
08/05/03



### APPLICATION ELEMENTS

- |   |              |                                 |
|---|--------------|---------------------------------|
| 1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17)<br><i>(Submit an original and a duplicate for fee processing)</i>  | Total Pages  | <input type="text" value="67"/> |
| 2. <input checked="" type="checkbox"/> Specification<br><i>(preferred arrangement set forth below)</i><br>- Descriptive title of the Invention<br>- Cross References to Related Applications<br>- Statement Regarding Fed sponsored R & D<br>- Reference to Microfiche Appendix<br>- Background of the Invention<br>- Brief Summary of the Invention<br>- Brief Description of the Drawings <i>(if filed)</i><br>- Detailed Description<br>- Claim(s)<br>- Abstract of the Disclosure | Total Pages  | <input type="text" value="67"/> |
| 3. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113)  | Total Sheets | <input type="text"/>            |
| 4. Oath or Declaration  | Total Pages  | <input type="text" value="2"/>  |
| a. <input checked="" type="checkbox"/> Newly unexecuted (original or copy)  |              |                                 |
| b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))  |              |                                 |
| i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u><br>Signed statement attached deleting inventor(s) named in the prior<br>application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).   |              |                                 |
| 5. Power of Attorney  | Total Pages  | <input type="text"/>            |
| a. <input type="checkbox"/> Newly executed (original or copy)   |              |                                 |
| b. <input type="checkbox"/> Copy from a prior application (37 CFR § 1.63(d))  |              |                                 |
| 6. <input type="checkbox"/> Microfiche Computer Program (Appendix)  |              |                                 |

7. Nucleotide and/or Amino Acid Sequence Submission  
*(if applicable, all necessary)*
- a.  Computer Readable Copy
  - b.  Paper Copy (identical to computer copy)
  - c.  Statement verifying identity of above copies

If a CONTINUING Application, check appropriate box, and supply the requisite information:

Continuation     Divisional     Continuation-in-part

of prior application no: \_\_\_\_\_, filed \_\_\_\_\_,

Examiner \_\_\_\_\_, Group/Art Unit \_\_\_\_\_.

(The cross reference has been/will be inserted on page one of the specification).

- This application claims the benefit of U.S. Provisional Application No. 60/432,314, filed December 10, 2002.
- This application claims the priority of European Application No. 02017585.7, filed August 7, 2002.
- Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

#### ACCOMPANYING APPLICATION PARTS

- 7.  Assignment Papers (*cover sheet & document(s)*)
- 8.  37 CFR §3.73(b) Statement  
*(when there is an assignee)*
- 9.  Verified English Translation Document (*if applicable*)
- 10.  Information Disclosure Statement (IDS)/PTO-1449       Copies of IDS Citations
- 11.  Preliminary Amendment
- 12.  Return Receipt Postcard (MPEP 503)  
*(Should be specifically itemized)*
- 13.  \*Small Entity Statement(s)       Statement filed in prior application,  
*(PTO/SB/09-12)* Status still proper and desired
- 14.  Certified Copy of Priority Document(s) - European Priority 02017585.7 (August 7, 2002)  
*(if foreign priority is claimed)*
- 15.  Other: Application Data Sheet (ePAVE)

#### CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487
<i>(Insert Customer No. or Attach bar code label here)</i>

  
Jiang Lin, Reg. No. 51,065  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3582  
Telefax (908) 231-2626  
Aventis Docket No. **DEAV2002/0056 US NP**

13049 U.S. PATENT E TRANSMITTAL  
for FY 2003

8/05/03

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$750.00)

## Complete if Known

Application Number	Not Yet Known
Filing Date	08/05/03
First Named Inventor	STROBEL
Examiner Name	Not Yet Known
Group / Art Unit	

Attorney Docket No. DEAV2002/0056 US NP

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)			
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input checked="" type="checkbox"/> Deposit Account				<b>3. ADDITIONAL FEES</b>			
Deposit Account Number		18-1982		Large Entity	Small Entity		
Deposit Account Name		Aventis Pharmaceuticals Inc.		Fee Code	Fee (\$)	Fee Code	Fee (\$)
<b>The Commissioner is authorized to:</b> (check all that apply) <input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments <input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account							
<b>FEE CALCULATION</b>							
<b>1. BASIC FILING FEE</b>							
Large Entity		Small Entity		Fee Description	Fee Paid		
Fee Code	Fee (\$)	Fee Code	Fee (\$)				
1001	750	2001	375	Utility filing fee	750		
1002	330	2002	165	Design filing Fee			
1003	520	2003	260	Plant filing fee			
1004	750	2004	375	Reissue filing fee			
1005	160	2005	80	Provisional filing fee			
<b>SUBTOTAL (1)</b>		<b>(\$750.00)</b>					
<b>2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE</b>							
		Extra Claims	Fee from below	Fee Paid			
Total Claims		10	-20**=	=			
Independent Claims		1	- 3**=	=			
Multiple Dependent			=				
Large Entity		Small Entity		Fee Description			
Fee Code	Fee (\$)	Fee Code	Fee (\$)				
1202	18	2202	9	Claims in excess of 20			
1201	84	2201	42	Independent claims in excess of 3			
1203	280	2203	140	Multiple dependent claim, if not paid			
1204	84	2204	42	**Reissue independent claims over original patent			
1205	18	2205	9	**Reissue claims in excess of 20 and over original patent			
<b>SUBTOTAL (2)</b>		<b>(\$0.00)</b>					
**or number previously paid, if greater; For Reissues, see above							
				*Reduced by Basic Filing Fee Paid <b>SUBTOTAL (3)</b> <b>(\$0.00)</b>			

## SUBMITTED BY

## Complete (If applicable)

Name (Print/Type)	Jiang Lin, Reg. No. 51,065	Registration No. (Attorney/Agent)	51,065	Telephone	(908) 231-3582
Signature				Date	August 5, 2003

**WARNING:Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Arlington, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template